Mitomycin-C versus oxaliplatin during cytoreductive surgery and HIPEC for peritoneal metastases secondary to colorectal carcinoma: a retrospective analysis.

John Spiliotis,Vasileios Kalles,Anastasia Prodromidou, Apostolos Raptis,Marios Ferfelis, Athina Christopoulou, Marios Tsiatas

Journal of B.U.ON. : official journal of the Balkan Union of Oncology（2021）

引用 0|浏览3

暂无评分

摘要

Our results imply that the use of MMC offers a survival advantage over oxaliplatin when used for HIPEC in CRC PC. A randomised trial comparing oxaliplatin and MMC would enhance decision-making in such patients.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要